Consensus on hemophilia in Mexico

Abstract

Hemophilia is a hemorrhagic disorder with a sex-linked inherited pattern, characterized by an inability to amplify coagulation due to a deficiency in coagulation factor VIII (hemophilia A or classic) or factor IX (hemophilia B). Sequencing of the genes involved in hemophilia has provided a description and record of the main mutations, as well as a correlation with the various degrees of severity. Hemorrhagic manifestations are related to levels of circulating factor, mainly affecting the musculoskeletal system and specifically the large joints (knees, ankles, and elbows). This document is a review and consensus of the main genetic aspects of hemophilia, from the inheritance pattern to the concept of women carriers, physiopathology and classification of the disorder, the basic and confirmation studies when hemophilia is suspected, the various treatment regimens based on infusion of the deficient coagulation factor as well as innovative factor-free therapies and recommendations for the management of complications associated with treatment (development of inhibitors and/or transfusion-transmitted infections), or secondary to articular hemorrhagic events (hemophilic arthropathy). Finally, relevant reviews of clinical and treatment aspects of hemorrhagic pathology characterized by acquired deficiency of FVIII secondary to neutralized antibodies named acquired hemophilia.

Prophylaxis and hemophilia care in LATAM: Baring it all—Highlights from the CLAHT 2021 symposium

“…Established agreements: Mexico is in transition toward the consolidated purchase model and is working on a standardization of treatment throughout all institutions [7]. The per capita indicator should ideally be >4 IU, with an approximate acquisition of more than 550 million units (80% of the acquisitions of factor VIII products should be of recombinant origin, and the remaining ones should be plasma derived).…”